Top

Published in:

Open Access 01-12-2009 | Research

Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area

Authors: Bianca Ervatti Gama, Natália K Almeida de Oliveira, Mariano G Zalis, José Maria de Souza, Fátima Santos, Cláudio Tadeu Daniel-Ribeiro, Maria de Fátima Ferreira-da-Cruz

Published in: Malaria Journal | Issue 1/2009

Abstract

Background

The goal of the present study was the characterization of Plasmodium falciparum genes associated to malaria drug resistance (pfcrt, pfdhfr and pfdhps), in samples from two Brazilian localities.

Methods

Parasites from 65 P. falciparum samples were genotyped using nested-PCR and direct DNA sequencing.

Results

Six resistant sulphadoxine-pyrimethamine (SP) pfdhfr genotypes and one haplotype associated to SP sensitivity were detected. For pfcrt gene, SVMNT chloroquine (CQ)-resistant genotype was detected as well as the CVMNK CQ-sensitive haplotype in the same sample from Paragominas, that showed a SP-sensitive genotype.

Conclusion

This study is the first to document the sensitivity of P. falciparum parasites to CQ and SP in Brazilian field samples. The importance of these findings is discussed.

Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF: Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg. 1998, 58: 630-637.PubMed

Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, Zalis MG: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000, 95: 721-728. 10.1590/S0074-02762000000500020.CrossRefPubMed

Alecrim WD, Dourado H, Alecrim M, das G, Passos LF, Wanssa E, Albuquerque B: In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level, in Amazonas, Brazil. Rev Inst Med Trop Sao Paulo. 1982, 24 (6 Suppl): 52-53.PubMed

da Silva J, Lopes PF, Ferreira LF, Morteo R, Navieira JB: Resistance of P. falciparum to the action of chloroquine. Hospital (Rio J). 1961, 60: 581-594.

Souza JM: Epidemiological distribution of Plasmodium falciparum drug resistance in Brazil and its relevance to the treatment and control of malaria. Mem Inst Oswaldo Cruz. 1992, 87: 343-348.CrossRefPubMed

Andrade JG, Andrade AL, Araujo ES, Oliveira RM, Silva AS, Martelli CM, Zicker F: A randomized clinical trial with high dose of chloroquine for treatment of Plasmodium falciparum malaria in Brazil. Rev Inst Med Trop Sao Paulo. 1992, 34 (5): 467-473.CrossRefPubMed

Camargo LMA, Oliveira S, Basano S, Garcia CRS: Antimalarials and the fight against malaria in Brazil. Vasc Health Risk Manag. 2009, 5: 1-7.CrossRef

WHO: Malaria treatment update. [http://www.who.int/malaria/rbm/Attachment/20041108/pr8nov2004.htm]

Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg. 2003, 68: 413-415.PubMed

10.

Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV: Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003, 187: 1870-1875. 10.1086/375419.CrossRefPubMed

11.

Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X, Wellems TE: Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am J Trop Med Hyg. 2005, 72: 410-414.PubMed

12.

Zhou Z, Griffing SM, de Oliveira AM, McCollum AM, Quezada WM, Arrospide N, Escalante AA, Udhayakumar V: Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob Agents Chemother. 2008, 52: 739-741. 10.1128/AAC.00975-07.PubMedCentralCrossRefPubMed

13.

Bacon DJ, McCollum AM, Griffing SM, Salas C, Soberon V, Santolalla M, Haley R, Tsukayama P, Lucas C, Escalante AA, Udhayakumar V: Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob Agents Chemother. 2009, 53: 2042-2051. 10.1128/AAC.01677-08.PubMedCentralCrossRefPubMed

14.

Talisuna AO, Bloland P, D'Alessandro U: History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004, 17: 235-254. 10.1128/CMR.17.1.235-254.2004.PubMedCentralCrossRefPubMed

15.

Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C: Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother. 2003, 47: 1347-1354. 10.1128/AAC.47.4.1347-1354.2003.PubMedCentralCrossRefPubMed

16.

Otto TD, Vasconcellos EA, Gomes LHF, Moreira AS, Degrave WM, Mendonça-Lima L, Alves-Ferreira M: ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility. Genet Mol Res. 2008, 7: 861-871. 10.4238/vol7-3X-Meeting04.CrossRefPubMed

17.

Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997, 176: 1590-1596. 10.1086/514159.CrossRefPubMed

18.

Vieira PP, Ferreira MU, Alecrim MG, Alecrim WD, da Silva LH, Sihuincha MM, Joy DA, Mu J, Su XZ, Zalis MG: Pfcrt polymorphism and the spread of chloroquine resistance in Plasmodium falciparum populations across the Amazon Basin. J Infect Dis. 2004, 190: 417-424. 10.1086/422006.CrossRefPubMed

19.

Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, Kumar A, Ansari MA, Sharma YD: Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob Agents Chemother. 2004, 48: 879-889. 10.1128/AAC.48.3.879-889.2004.PubMedCentralCrossRefPubMed

20.

Contreras CE, Cortese JF, Caraballo A, Plowe CV: Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am J Trop Med Hyg. 2002, 67: 400-405.PubMed

21.

Mita T, Kaneko A, Lum JK, Zungu IL, Tsukahara T, Eto H, Kobayakawa T, Björkman A, Tanabe K: Expansion of wild type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol Biochem Parasitol. 2004, 135: 159-163. 10.1016/j.molbiopara.2004.01.011.CrossRefPubMed

Title: Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area
Authors: Bianca Ervatti Gama
Natália K Almeida de Oliveira
Mariano G Zalis
José Maria de Souza
Fátima Santos
Cláudio Tadeu Daniel-Ribeiro
Maria de Fátima Ferreira-da-Cruz
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Malaria Journal / Issue 1/2009
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/1475-2875-8-156

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Access to malaria treatment in young children of rural Burkina Faso

Limitation of using synthetic human odours to test mosquito repellents

Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008

Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets

Anopheles mortality is both age- and Plasmodium-density dependent: implications for malaria transmission

Highly focused anopheline breeding sites and malaria transmission in Dakar

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials